Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267

1.

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.

Tan WL, Ng QS, Lim C, Tan EH, Toh CK, Ang MK, Kanesvaran R, Jain A, Tan DSW, Lim DW.

BMC Cancer. 2018 Dec 3;18(1):1198. doi: 10.1186/s12885-018-5110-2.

2.

Effects of Single Nucleotide Polymorphisms on the binding of afatinib to EGFR: a potential patient stratification factor revealed by modelling studies.

Kannan S, Tan DS, Verma CS.

J Chem Inf Model. 2018 Nov 27. doi: 10.1021/acs.jcim.8b00491. [Epub ahead of print]

PMID:
30481018
3.

Synthesis of the hexacyclic triterpene core of the jujuboside saponins via tandem Wolff rearrangement-intramolecular ketene hetero-Diels-Alder reaction.

Karimov RR, Tan DS, Gin DY.

Tetrahedron. 2018 Jun 28;74(26):3370-3383. doi: 10.1016/j.tet.2018.04.051. Epub 2018 Apr 19.

PMID:
30467444
4.

Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancer.

Tan TZ, Heong V, Ye J, Lim D, Low J, Choolani M, Scott C, Tan DSP, Huang RY.

J Pathol. 2018 Oct 30. doi: 10.1002/path.5191. [Epub ahead of print]

PMID:
30374975
5.
6.

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW.

J Clin Oncol. 2018 Aug 29:JCO2018777326. doi: 10.1200/JCO.2018.77.7326. [Epub ahead of print]

PMID:
30156984
7.

Comparison of rivaroxaban concentrations between Asians and Caucasians and their correlation with PT/INR.

Ng Tsai HO, Goh JJN, Aw JWX, Lin Y, Fong AYY, Tiong LL, Tan DS.

J Thromb Thrombolysis. 2018 Nov;46(4):541-548. doi: 10.1007/s11239-018-1726-y.

PMID:
30155672
8.

Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.

Subhash VV, Yeo MS, Wang L, Tan SH, Wong FY, Thuya WL, Tan WL, Peethala PC, Soe MY, Tan DSP, Padmanabhan N, Baloglu E, Shacham S, Tan P, Koeffler HP, Yong WP.

Sci Rep. 2018 Aug 16;8(1):12248. doi: 10.1038/s41598-018-30686-1.

9.

A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.

Lheureux S, Tinker A, Clarke B, Ghatage P, Welch S, Weberpals JI, Dhani NC, Butler MO, Tonkin K, Tan Q, Tan DSP, Brooks K, Ramsahai J, Wang L, Pham NA, Shaw PA, Tsao MS, Garg S, Stockley T, Oza AM.

Clin Cancer Res. 2018 Aug 14. doi: 10.1158/1078-0432.CCR-18-1244. [Epub ahead of print]

PMID:
30108107
10.

Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers.

Chan GHJ, Ong PY, Low JJH, Kong HL, Ow SGW, Tan DSP, Lim YW, Lim SE, Lee SC.

Oncotarget. 2018 Jul 17;9(55):30649-30660. doi: 10.18632/oncotarget.25769. eCollection 2018 Jul 17.

11.

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.

Harding JJ, Bauer TM, Tan DSW, Bedard PL, Rodon J, Doi T, Schnell C, Iyer V, Baffert F, Radhakrishnan R, Fabre C, Juric D.

Invest New Drugs. 2018 Aug 3. doi: 10.1007/s10637-018-0627-4. [Epub ahead of print]

PMID:
30073466
12.

DeepDemosaicking: Adaptive Image Demosaicking via Multiple Deep Fully Convolutional Networks.

Tan DS, Chen WY, Hua KL.

IEEE Trans Image Process. 2018 Feb 7. doi: 10.1109/TIP.2018.2803341. [Epub ahead of print]

PMID:
29994510
13.

Letter by Aw et al Regarding Article, "Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention".

Aw JWX, Tan DS, Goh LL.

Circ Genom Precis Med. 2018 Jul;11(7):e002253. doi: 10.1161/CIRCGEN.118.002253. No abstract available.

PMID:
29987115
14.

Synthesis of Benzannulated Medium-ring Lactams via a Tandem Oxidative Dearomatization-Ring Expansion Reaction.

Guney T, Wenderski TA, Boudreau MW, Tan DS.

Chemistry. 2018 Sep 6;24(50):13150-13157. doi: 10.1002/chem.201802880. Epub 2018 Aug 2.

PMID:
29936701
15.

Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.

Ngoi NYL, Heong V, Lee XW, Huang YQ, Thian YL, Choo BA, Lim D, Lim YW, Lim SE, Ilancheran A, Soong R, Tan DSP.

Gynecol Oncol Rep. 2018 Jan 31;24:1-5. doi: 10.1016/j.gore.2018.01.009. eCollection 2018 May.

16.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6. Review.

PMID:
29885479
17.

Biomarkers for Homologous Recombination Deficiency in Cancer.

Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD.

J Natl Cancer Inst. 2018 Jul 1;110(7):704-713. doi: 10.1093/jnci/djy085.

PMID:
29788099
18.

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.

Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H, Duan K, Ang N, Poidinger M, Lee YY, Larbi A, Khng AJ, Tan E, Fu C, Mathew R, Teo M, Lim WT, Toh CK, Ong BH, Koh T, Hillmer AM, Takano A, Lim TKH, Tan EH, Zhai W, Tan DSW, Tan IB, Newell EW.

Nature. 2018 May;557(7706):575-579. doi: 10.1038/s41586-018-0130-2. Epub 2018 May 16.

PMID:
29769722
19.

Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency.

Simoni Y, Fehlings M, Kløverpris HN, McGovern N, Koo SL, Loh CY, Lim S, Kurioka A, Fergusson JR, Tang CL, Kam MH, Dennis K, Lim TKH, Fui ACY, Hoong CW, Chan JKY, Curotto de Lafaille M, Narayanan S, Baig S, Shabeer M, Toh SES, Tan HKK, Anicete R, Tan EH, Takano A, Klenerman P, Leslie A, Tan DSW, Tan IB, Ginhoux F, Newell EW.

Immunity. 2018 May 15;48(5):1060. doi: 10.1016/j.immuni.2018.04.028. No abstract available.

PMID:
29768165
20.

A Decade of Never-smokers Among Lung Cancer Patients-Increasing Trend and Improved Survival.

Toh CK, Ong WS, Lim WT, Tan DS, Ng QS, Kanesvaran R, Seow WJ, Ang MK, Tan EH.

Clin Lung Cancer. 2018 Sep;19(5):e539-e550. doi: 10.1016/j.cllc.2018.03.013. Epub 2018 Mar 17.

PMID:
29627315
21.

Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer.

Tan WL, Tan DSW.

Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S13-S18. doi: 10.21037/tlcr.2017.11.12. No abstract available.

22.

Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women.

Chay WY, Kwok LL, Tiong WN, Krisna SS, Lim KH, Iyer NG, Goh LK, Tan DS.

Int J Gynecol Cancer. 2018 Mar;28(3):428-436. doi: 10.1097/IGC.0000000000001138.

PMID:
29465505
23.

Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing.

Nahar R, Zhai W, Zhang T, Takano A, Khng AJ, Lee YY, Liu X, Lim CH, Koh TPT, Aung ZW, Lim TKH, Veeravalli L, Yuan J, Teo ASM, Chan CX, Poh HM, Chua IML, Liew AA, Lau DPX, Kwang XL, Toh CK, Lim WT, Lim B, Tam WL, Tan EH, Hillmer AM, Tan DSW.

Nat Commun. 2018 Jan 15;9(1):216. doi: 10.1038/s41467-017-02584-z.

24.

GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers.

Rasheed SAK, Leong HS, Lakshmanan M, Raju A, Dadlani D, Chong FT, Shannon NB, Rajarethinam R, Skanthakumar T, Tan EY, Hwang JSG, Lim KH, Tan DS, Ceppi P, Wang M, Tergaonkar V, Casey PJ, Iyer NG.

Oncogene. 2018 Mar;37(10):1340-1353. doi: 10.1038/s41388-017-0038-6. Epub 2017 Dec 19.

25.

Incidence of thromboembolic and bleeding events in patients with newly diagnosed nonvalvular atrial fibrillation: An Asian multicenter retrospective cohort study in Singapore.

Wee XT, Ho LM, Ho HK, Lee JY, Yap CW, William H, Chan LCE, Tay HC, Goh CEM, Tan DS.

Clin Cardiol. 2017 Dec;40(12):1218-1226. doi: 10.1002/clc.22811. Epub 2017 Dec 18.

26.

Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis.

Wang KL, Chiu CC, Giugliano RP, Tan DS, Lin CY, Lai EY, Goto S, Chiang CE.

J Stroke Cerebrovasc Dis. 2018 Apr;27(4):857-864. doi: 10.1016/j.jstrokecerebrovasdis.2017.10.027. Epub 2017 Nov 26. Review.

PMID:
29239808
27.

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Drilon A, Hu ZI, Lai GGY, Tan DSW.

Nat Rev Clin Oncol. 2018 Mar;15(3):150. doi: 10.1038/nrclinonc.2017.188. Epub 2017 Nov 28.

PMID:
29182164
28.

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Drilon A, Hu ZI, Lai GGY, Tan DSW.

Nat Rev Clin Oncol. 2018 Mar;15(3):151-167. doi: 10.1038/nrclinonc.2017.175. Epub 2017 Nov 14. Review. Erratum in: Nat Rev Clin Oncol. 2017 Nov 28;:.

PMID:
29134959
29.

A three gene immunohistochemical panel serves as an adjunct to clinical staging of patients with head and neck cancer.

Ong CJ, Shannon NB, Mueller S, Lek SM, Qiu X, Chong FT, Li K, Koh KKN, Tay GCA, Skanthakumar T, Hwang JSG, Hon Lim TK, Ang MK, Tan DSW, Tan NC, Tan HK, Soo KC, Iyer NG.

Oncotarget. 2017 Jun 19;8(45):79556-79566. doi: 10.18632/oncotarget.18568. eCollection 2017 Oct 3.

30.

Stereocontrolled Synthesis of Spiroketals: An Engine for Chemical and Biological Discovery.

Verano AL, Tan DS.

Isr J Chem. 2017 Apr;57(3-4):279-291. doi: 10.1002/ijch.201600134. Epub 2017 Mar 10.

31.

Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer.

Lau KW, Seng C, Lim TKH, Tan DSW.

Ann Transl Med. 2017 Sep;5(18):372. doi: 10.21037/atm.2017.08.42. Review.

32.

Improved Survival of Advanced Lung Cancer in Singapore Over the Past Decade.

Toh CK, Ong WS, Tan DS, Ng QS, Kanesvaran R, Fong KW, Ang MK, Tan EH, Lim WT.

Ann Acad Med Singapore. 2017 Sep;46(9):333-338.

33.

Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study.

Heong V, Syn NL, Lee XW, Sapari NS, Koh XQ, Adam Isa ZF, Sy Lim J, Lim D, Pang B, Thian YL, Ng LK, Wong AL, Soo RA, Yong WP, Chee CE, Lee SC, Goh BC, Soong R, Tan DSP.

Int J Cancer. 2018 May 1;142(9):1890-1900. doi: 10.1002/ijc.31091. Epub 2017 Oct 17.

PMID:
28994108
34.

Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.

Tan DSW, Chong FT, Leong HS, Toh SY, Lau DP, Kwang XL, Zhang X, Sundaram GM, Tan GS, Chang MM, Chua BT, Lim WT, Tan EH, Ang MK, Lim TKH, Sampath P, Chowbay B, Skanderup AJ, DasGupta R, Iyer NG.

Nat Med. 2017 Oct;23(10):1167-1175. doi: 10.1038/nm.4401. Epub 2017 Sep 18.

PMID:
28920960
35.

Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time.

Chia S, Low JL, Zhang X, Kwang XL, Chong FT, Sharma A, Bertrand D, Toh SY, Leong HS, Thangavelu MT, Hwang JSG, Lim KH, Skanthakumar T, Tan HK, Su Y, Hui Choo S, Hentze H, Tan IBH, Lezhava A, Tan P, Tan DSW, Periyasamy G, Koh JLY, Gopalakrishna Iyer N, DasGupta R.

Nat Commun. 2017 Sep 5;8(1):435. doi: 10.1038/s41467-017-00451-5.

36.

Family-level stereoselective synthesis and biological evaluation of pyrrolomorpholine spiroketal natural product antioxidants.

Verano AL, Tan DS.

Chem Sci. 2017 May 1;8(5):3687-3693. doi: 10.1039/c6sc05505b. Epub 2017 Mar 15.

37.

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors.

Lim JSJ, Tan DSP.

Cancers (Basel). 2017 Aug 22;9(8). pii: E109. doi: 10.3390/cancers9080109. Review.

38.

Harvesting more grain zinc of wheat for human health.

Chen XP, Zhang YQ, Tong YP, Xue YF, Liu DY, Zhang W, Deng Y, Meng QF, Yue SC, Yan P, Cui ZL, Shi XJ, Guo SW, Sun YX, Ye YL, Wang ZH, Jia LL, Ma WQ, He MR, Zhang XY, Kou CL, Li YT, Tan DS, Cakmak I, Zhang FS, Zou CQ.

Sci Rep. 2017 Aug 1;7(1):7016. doi: 10.1038/s41598-017-07484-2.

39.

Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade.

Tan DSW.

J Clin Oncol. 2017 Aug 20;35(24):2735-2736. doi: 10.1200/JCO.2017.73.6215. Epub 2017 Jul 17. No abstract available.

PMID:
28715246
40.

Development of PARP inhibitors in gynecological malignancies.

Ang YLE, Tan DSP.

Curr Probl Cancer. 2017 Jul - Aug;41(4):273-286. doi: 10.1016/j.currproblcancer.2017.02.008. Epub 2017 Mar 14. Review.

PMID:
28583748
41.
42.

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib.

Kannan S, Pradhan MR, Tiwari G, Tan WC, Chowbay B, Tan EH, Tan DS, Verma C.

Sci Rep. 2017 May 8;7(1):1540. doi: 10.1038/s41598-017-01491-z.

43.

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.

Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT.

Oncotarget. 2017 Jun 20;8(25):41474-41486. doi: 10.18632/oncotarget.17102. Review.

44.

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM.

Cancer Treat Rev. 2017 Apr;55:181-189. doi: 10.1016/j.ctrv.2017.03.006. Epub 2017 Mar 30. Review.

45.

Targeting the AXL signaling pathway in ovarian cancer.

Huang RY, Antony J, Tan TZ, Tan DS.

Mol Cell Oncol. 2016 Nov 28;4(2):e1263716. doi: 10.1080/23723556.2016.1263716. eCollection 2017.

46.

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr.

Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24. Erratum in: Lancet. 2017 Mar 4;389(10072):908.

PMID:
28126333
47.

Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study.

Sundar R, Bandla A, Tan SS, Liao LD, Kumarakulasinghe NB, Jeyasekharan AD, Ow SG, Ho J, Tan DS, Lim JS, Vijayan J, Therimadasamy AK, Hairom Z, Ang E, Ang S, Thakor NV, Lee SC, Wilder-Smith EP.

Front Oncol. 2017 Jan 10;6:274. doi: 10.3389/fonc.2016.00274. eCollection 2016.

48.

Identifying Potentially Avoidable Readmissions: A Medication-Based 15-Day Readmission Risk Stratification Algorithm.

Dorajoo SR, See V, Chan CT, Tan JZ, Tan DS, Abdul Razak SM, Ong TT, Koomanan N, Yap CW, Chan A.

Pharmacotherapy. 2017 Mar;37(3):268-277. doi: 10.1002/phar.1896. Epub 2017 Feb 20.

PMID:
28052412
49.

Update on immune checkpoint inhibitors in gynecological cancers.

Heong V, Ngoi N, Tan DS.

J Gynecol Oncol. 2017 Mar;28(2):e20. doi: 10.3802/jgo.2017.28.e20. Epub 2016 Dec 14. Review.

50.

Supplemental Content

Support Center